Abstract
Abrocitinib (Cibinqo) is a new janus kinase inhibitor for the treatment of moderate to severe atopic dermatitis in adults and adolescents. This article reviews its properties and place in therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.